13 Stocks to Buy with Exponential Growth Heading into 2026
As per Fidelity, the tax law that was passed over the summer is projected to reduce the effective corporate tax rate.
Summit Therapeutics Inc. (SMMT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 33,722,974 | $717,624,887 | +39% | 6.96% |
| 2. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,000,000 | $21,280,000 | 0.11% | |
| 3. | Polymer Capital Management Angus Yuk Chi Wai | 890,029 | $18,939,817 | +125% | 2.86% |
| 4. | 869,700 | $18,507,216 | +3854% | 0.02% | |
| 5. | 863,100 | $18,366,768 | +237% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.74 | 533,617 | $9,999,982.58 | 32,057,147 | 2025-10-21 | Filing | |
| $18.74 | 26,680 | $499,983.20 | 76,680 | 2025-10-21 | Filing | |
| $18.74 | 26,680 | $499,983.20 | 76,680 | 2025-10-21 | Filing | |
| $18.07 | 5,000 | $90,350.00 | 556,093,090 | 2025-09-11 | Filing | |
| $17.68 | 333,394 | $5,894,405.92 | 556,088,090 | 2025-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.44 | 13,713 | $60,885.72 | 0 | 2020-11-30 | Filing | |
| $4.39 | 29,569 | $129,807.91 | 0 | 2020-11-27 | Filing | |
| $4.32 | 12,070 | $52,142.40 | 0 | 2020-11-25 | Filing | |
| $4.21 | 11,374 | $47,884.54 | 0 | 2020-11-24 | Filing | |
| $4.40 | 6,987 | $30,742.80 | 0 | 2020-11-23 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,310,941 | $27,084,041 | 12.87% | |
| 2. | 496,266 | $10,252,856 | 3.44% | |
| 3. | 202,618 | $4,186,088 | 0% | |
| 4. | 140,282 | $2,898,226 | 0.33% | |
| 5. | 114,657 | $2,368,814 | 0% |
News See All
10 Stocks Under $20 to Buy According to Analysts
On Tuesday, October 28, all the three major averages finished at new heights. The broad market S&P 500 went up by 0.23%.
13 Best Growth Stocks Under $25 to Buy Right Now
Recently, there have been concerns around the surge of fraudulent loans and private credit quality issues in the US.
Where is Summit Therapeutics (SMMT) Headed According to Analysts?
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks with high potential.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best biotech stocks to buy. On September 16, H.C. Wainwright reaffirmed its $50 price target and Buy rating for Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company focused on oncology, developing therapies for non-small cell lung cancer (NSCLC) and other unmet medical needs.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
12 Healthcare Stocks with Insider Buying in 2025
In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, with divergent trends in technology adoption, investment, and fundraising.
Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China
Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical company focused on non-small cell lung cancer (NSCLC), has made significant strides with its lead investigational drug, ivonescimab.
Hedge Fund Resource Center Billionaire Hedge Funds
